BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

356 related articles for article (PubMed ID: 10600203)

  • 1. Acellular pertussis vaccines: neutralization by immune sera of the lethality of pertussis toxin and viable Bordetella pertussis for chick embryos.
    Calver GA
    Biologicals; 1999 Jun; 27(2):143-7. PubMed ID: 10600203
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chick embryo, a model to study the lethal activity of pertussis toxin, infectivity of Bordetella pertussis, and their neutralization by immune sera.
    Calver GA; Burton WW; Gardell CY
    Can J Microbiol; 1993 Aug; 39(8):759-66. PubMed ID: 8106134
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Description and evaluation of serologic assays used in a multicenter trial of acellular pertussis vaccines.
    Meade BD; Deforest A; Edwards KM; Romani TA; Lynn F; O'Brien CH; Swartz CB; Reed GF; Deloria MA
    Pediatrics; 1995 Sep; 96(3 Pt 2):570-5. PubMed ID: 7659478
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Relationships between functional assays and enzyme immunoassays as measurements of responses to acellular and whole-cell pertussis vaccines.
    Meade BD; Lynn F; Reed GF; Mink CM; Romani TA; Deforest A; Deloria MA
    Pediatrics; 1995 Sep; 96(3 Pt 2):595-600. PubMed ID: 7659484
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Cellular and acellular anti-pertussis vaccines].
    Locht C
    Ann Pharm Fr; 2001 May; 59(3):198-205. PubMed ID: 11427821
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Engineering bacterial toxin for the development of new vaccine against pertussis.
    Bartoloni A; Pizza M; Gross R; Perugini M; Arico B; Domenighini M; Rappuoli R
    Tokai J Exp Clin Med; 1988; 13 Suppl():217-22. PubMed ID: 2483870
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of a tetraplex microsphere assay for Bordetella pertussis antibodies.
    Prince HE; Lapé-Nixon M; Matud J
    Clin Vaccine Immunol; 2006 Feb; 13(2):266-70. PubMed ID: 16467336
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Further characterization of Japanese acellular pertussis vaccine prepared in 1988 by 6 Japanese manufacturers.
    Sato Y; Sato H
    Tokai J Exp Clin Med; 1988; 13 Suppl():79-88. PubMed ID: 2908530
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Humoral response to the injection of acellular Pertussis vaccine].
    Zakharova NS; Remova TN; Britsina MV; Shmeleva EI; Mertsalova NU; Zaĭtsev EM; Ozeretskovskaia MN; Bazhanova IG; Ermolova EV
    Zh Mikrobiol Epidemiol Immunobiol; 2001; (6):40-4. PubMed ID: 11881494
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of serum treatment on pertussis antibody determination by ELISA.
    Tada Y; Ishikawa T; Chazono M; Yoshida I; Nii R
    Dev Biol Stand; 1991; 73():175-84. PubMed ID: 1778311
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Specific anti-Bordetella pertussis activities in human blood examined by enzyme-linked immunoassay and biological assay.
    Marley PB; Wilson JV; Habel H; Blaskett A
    Dev Biol Stand; 1985; 61():341-52. PubMed ID: 2872123
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Verification of components of acellular pertussis vaccines that have been distributed solely, been in routine use for the last two decades and contributed greatly to control of pertussis in Japan.
    Kuno-Sakai H; Kimura M; Watanabe H
    Biologicals; 2004 Mar; 32(1):29-35. PubMed ID: 15026023
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Production and purification of Bordetella pertussis toxin.
    Ju CL; Sheu GC; Cheng Y; Lu CH
    Zhonghua Min Guo Wei Sheng Wu Ji Mian Yi Xue Za Zhi; 1997 May; 30(2):72-83. PubMed ID: 10592813
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prevalence of pertussis antibodies in maternal delivery, cord, and infant serum.
    Healy CM; Munoz FM; Rench MA; Halasa NB; Edwards KM; Baker CJ
    J Infect Dis; 2004 Jul; 190(2):335-40. PubMed ID: 15216470
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [The immunological basis of the administration of DTP-polio vaccine].
    Cohen H
    Verh K Acad Geneeskd Belg; 2000; 62(4):245-67. PubMed ID: 11004905
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A rapid ELISA-based method for screening Bordetella pertussis strain production of antigens included in current acellular pertussis vaccines.
    Barkoff AM; Guiso N; Guillot S; Xing D; Markey K; Berbers G; Mertsola J; He Q
    J Immunol Methods; 2014 Jun; 408():142-8. PubMed ID: 24925807
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Standardization of acellular pertussis vaccine by assay of serum neutralizing antibodies to pertussis toxin (antitoxin): analogy with diphtheria toxoid.
    Robbins JB; Schneerson R; Trollfors B; Taranger J; Lagergård T
    Dev Biol Stand; 1998; 95():155-8. PubMed ID: 9855426
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serum antibody response to B. pertussis Tn5 mutants, purified PT and FHA in two different mouse strains and passive protection in the murine intranasal infection model.
    Olander RM; Muotiala A; Karvonen M; Kuronen T; Runeberg-Nyman K
    Microb Pathog; 1990 Jan; 8(1):37-45. PubMed ID: 2159104
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Collaborative study on a Guinea pig serological method for the assay of acellular pertussis vaccines.
    Winsnes R; Sesardic D; Daas A; Terao E; Behr-Gross ME
    Pharmeur Bio Sci Notes; 2009 Oct; 2009(1):27-40. PubMed ID: 20144450
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Collaborative study for the standardisation of the histamine sensitizing test in mice and the CHO cell-based assay for the residual toxicity testing of acellular pertussis vaccines.
    Xing D; Maes A; Behr-Gross ME; Costanzo A; Daas A; Buchheit KH
    Pharmeur Bio Sci Notes; 2010 Apr; 2010(1):51-63. PubMed ID: 20223190
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.